Klaudia Pacewicz and Paulina Nawrocka-Muszynska presented preliminary findings showing how machine learning algorithms can predict response to immune checkpoint inhibitors (ICIs) with greater precision than any standard biomarkers. Our algorithm developed on non-small-cell lung carcinoma patients treated with pembrolizumab/nivolumab achieved great results with an accuracy of 0.88.
Incredible data emphasizing the power of genomic-based and AI research presented at ESMO makes us extremely excited about the future of the fight against cancer. We are so proud that our work actively contributes to the development of innovative medicine.
